Author:
Hughes A R,Spreen W R,Mosteller M,Warren L L,Lai E H,Brothers C H,Cox C,Nelsen A J,Hughes S,Thorborn D E,Stancil B,Hetherington S V,Burns D K,Roses A D
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Reference30 articles.
1. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23: 1603–1614.
2. Cutrell A, Hernandez J, Edwards M, Fleming J, Powell W, Scott T . Clinical risk factors for hypersensitivity reactions to abacavir: retrospective analysis of over 8000 subjects receiving abacavir in 34 clinical trials. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 14–17 September 2003; Chicago, IL; Abstract H-2013.
3. Keiser P, Nassar N, Skiest D, Andrews C, Yazdani B, White A et al. Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction. Int J STD AIDS 2003; 14: 478–481.
4. Cutrell AG, Hernandez JE, Fleming JW, Edwards MT, Moore MA, Brothers CH et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004; 38: 2171–2172.
5. United States Code of Federal Regulations, 21 CFR Part 314, Subpart H (accelerated approval). Office of the Federal Register National Archives and Records Administration: Washington, DC, 2007.
Cited by
74 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献